<DOC>
	<DOCNO>NCT01968551</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) fix dose combination ( FDC ) plus DRV relative current antiretroviral regimen ( ARV ) virologically suppress , HIV-1 positive participant HIV-1 RNA &lt; 50 copies/mL Week 24 . This study consist 48 week open-label phase follow optional extension phase participant receive E/C/F/TAF+DRV .</brief_summary>
	<brief_title>Phase 3 Open-Label Study Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( E/C/F/TAF ) Fixed Dose Combination ( FDC ) Plus Darunavir ( DRV ) Treatment Experienced HIV-1 Positive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Ability understand sign write informed consent form History least two prior antiretroviral regimen , history resistance least two different class antiretroviral agent Plasma HIV1 RNA level &lt; 50 copies/mL screening . Virologically suppressed current antiretroviral regimen contain darunavir 600 mg twice day 800 mg daily continuously ≥ 4 month precede screen visit maintain document undetectable plasma HIV 1 RNA level ( &lt; 50 copies/mL ) must documentation genotype/phenotype prior current regimen show darunavir associate resistance mutation . Currently receive raltegravir , elvitegravir , dolutegravir ( 50 mg daily , twice daily ) available documentation genotype/phenotype within 12 month prior current regimen must show evidence resistance integrase inhibitor Normal ECG Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min accord Cockcroft Gault formula creatinine clearance Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm3 ; platelet ≥ 50,000/mm3 ; hemoglobin ≥ 8.5 g/dL ) Serum amylase ≤ 5 × ULN ( individual serum amylase &gt; 5 × ULN remain eligible serum lipase ≤ 5 × ULN ) A female individual eligible enter study confirm : Not pregnant nursing Of nonchildbearing potential ( i.e. , woman hysterectomy , ovary remove medically document ovarian failure , postmenopausal woman &gt; 54 year age cessation ( ≥ 12 month ) previously occur menses ) , Of childbearing potential agrees utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 30 day follow study drug dosing . Female individual utilize hormonal contraceptive one birth control method must use method least three month prior study dose . Male individual must agree utilize highly effective method contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence first dose throughout study period 30 day follow last study drug dose . Male individual must agree refrain sperm donation first dose least 30 day last study drug dose . A new AIDSdefining condition diagnose within 30 day prior screen ( except CD4 cell count and/or percentage criterion ) Hepatitis B surface antigen ( HBsAg ) positive Individuals receive drug treatment Hepatitis C , individual anticipate receive treatment Hepatitis C course study . Must Q151M , T69ins , &gt; 3 TAMS present document historic genotype report Individuals experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance use may interfere individual 's study compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 visit Any clinical condition prior therapy would make individual unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval sponsor prohibit participate trial Individuals receive ongoing therapy disallow medication , include drug use elvitegravir , cobicistat , emtricitabine , TAF , DRV ; individual know allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-Experienced</keyword>
</DOC>